Anti-C1-inactivator treatment of glioblastoma

Karolina Förnvik; Jonatan Ahlstedt; Kurt Osther; Leif G. Salford; Henrietta Nittby Redebrandt

doi:10.18632/oncotarget.26456

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Anti-C1-inactivator treatment of glioblastoma

Karolina Förnvik _, Jonatan Ahlstedt, Kurt Osther, Leif G. Salford and Henrietta Nittby Redebrandt

PDF | HTML | How to cite

Oncotarget. 2018; 9:37421-37428. https://doi.org/10.18632/oncotarget.26456

Metrics: PDF 1128 views | HTML 1693 views | ?

Abstract

Karolina Förnvik1,2, Jonatan Ahlstedt1, Kurt Osther1, Leif G. Salford1 and Henrietta Nittby Redebrandt1,3

1The Rausing Laboratory, Division of Neurosurgery, Department of Clinical Sciences, Lund University, Lund, Sweden

2Department of Clinical Chemistry, Skåne University Hospital, Lund, Sweden

3Department of Neurosurgery, Skåne University Hospital, Lund, Sweden

Correspondence to:

Karolina Förnvik, email: [email protected]

Keywords: complement; C1-inactivator; glioblastoma

Received: September 13, 2018 Accepted: November 26, 2018 Published: December 21, 2018

ABSTRACT

Purpose: Glioblastoma multiforme (GBM) or astrocytoma grade IV is the most common type of primary brain tumor in adults. In the present study, we investigate the role of the complement system in the glioblastoma situation in an experimental model, since we have previously been able to show a blockade of this system in the glioblastoma setting.

Technique and results: A GFP-positive glioblastoma cell line was used to induce glioblastomas subcutaneously in rats (n=42). Antibodies against C1-Inactivator (C1-IA) were used to try to re-activate the complement system. We were able to demonstrate an increased survival in rats treated with anti-C1-IA with an intratumoral route, and we could establish the same the results in a second series. Serum analyses revealed decreased levels of IL-1b and GM-CSF in animals 24 days after tumor cell inoculation in the anti-C1-IA group when compared to controls. Immunohistochemistry revealed decreased expression of C1-IA following treatment.

Interpretation: These results are in line with our previous work showing an upregulation of C1-IA, which is able to block the classical complement pathway, in glioblastomas. Treatment with antibodies against C1-IA seems to be beneficial in the glioblastoma situation, and no side effects could be seen in our experiments.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 26456

Publication Alerts

Research Papers:

Anti-C1-inactivator treatment of glioblastoma

Abstract